LARCHMONT, N.Y.--(BUSINESS WIRE)--Nov. 4, 2003--Innovative treatment strategies in development for combating Alzheimer's disease and related neurodegenerative disorders will be the focus of a lively and informative session entitled "Exploring New Frontiers in Alzheimer's Disease" at the Fourth Annual Conference on Regenerative Medicine, November 17-19, 2003, in Washington, D.C. "Rebuilding the Body, Restoring Function," is the focus of this year's conference, which is jointly sponsored by Genetic Engineering News, a publication of Mary Ann Liebert, Inc. (www.liebertpub.com), the University of South Florida College of Medicine, and the Regenerative Medicine and Stem Cell Biology Society, and is presented by BioConferences International. The complete program including summaries of the presentations can be viewed at www.bioconferences.com/ebio
Session Chair Michael Wolfe, Ph.D., Associate Professor at Harvard Medical School/Brigham and Women's Hospital, has gathered a forward-thinking group of speakers on cutting-edge research at major research institutions on the cause of Alzheimer's disease and on drug, gene, and vaccine therapies aimed at preventing, curing, and slowing the progression of the brain pathology and cognitive decline that is characteristic of this disorder.
John Hardy, Ph.D., of the National Institute on Aging will discuss the role amyloid beta protein plays in the initiation of Alzheimer's disease in his talk, "Subtle Differences in Protein Quantity Underlie Initiation of Neurodegenerative Diseases." A key challenge in treating diseases affecting the central nervous system is developing therapies that are able to cross the blood-brain barrier. William Pardridge, M.D., Professor of Medicine at the University of California, Los Angeles, will present on "Drug and Gene Delivery to the Brain: The Trans-Vascular Route."
Therapeutic vaccines that stimulate the immune system to target and destroy amyloid beta protein have shown promise in preclinical testing. Cynthia Lemere, Ph.D., Assistant Professor at Harvard Medical School provides an up-to-date look at "Beta Amyloid Immunization Therapy." Michael Wolfe explores novel drug targets in a presentation entitled "Secretase Targets for Alzheimer's Disease."
World-class scientists from leading academic centers, industry, and government research institutions will also present their most recent findings during conference sessions that will focus on Cellular Therapies: Repairing the Damaged and Worn Body, Substitutive Medicine: Organ Replacement and Repair, and Tissue Engineering.
Robert Langer, Ph.D. (MIT), will present the Keynote Address, entitled "Novel Biomaterials." In the New Ventures Address, Linda Powers, Managing Director of Toucan Capital, will provide a detailed overview of the current economic environment and discuss the opportunities and obstacles for early-stage funding.
For more information about the Fourth Annual Conference on Regenerative Medicine, including registration, submitting a poster abstract, sponsorships, and exhibits, please contact email@example.com, (800) 5-BIOCON, (914) 834-3100, ext. 608, fax (914) 834-3689.
Mary Ann Liebert, Larchmont Harriet Matysko, 914-834-3100, ext. 608
Source: Mary Ann Liebert